In this video, Nicholas Short, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares some insights into the safety and efficacy of hyper-CVAD (cyclophosphamide, vincristine, doxorubicin and dexamethasone) in combination with blinatumomab and inotuzumab ozogamicin in patients with Ph- acute lymphoblastic leukemia (ALL), highlighting the overall responses rates (ORR) and measurable residual disease (MRD) negative responses observed with this combination. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.